Senti Biosciences

SNTI · NASDAQ

$0.2277+$0.0009 (+0.40%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $0.2268

SNTI analyst rating

BuyConsensus of 2 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy2
Hold0
Underperform0
Sell0

12-month price target · 5 analysts

Average $11.22 (+4827.5% upside)

Low: $6.06
Now: $0.2277
High: $15.75

Upgrades and downgrades

The latest rating actions, newest first

SNTI analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Chardan Capital	May 15, 2026	Maintains	Buy	$11.00 → $12.00	43%
Chardan Capital	Mar 30, 2026	Maintains	Buy	$13.00 → $11.00	43%
Chardan Capital	Dec 9, 2025	Maintains	Buy	$12.00 → $13.00	43%
Leerink Partners	Nov 21, 2025	Initiates	Outperform	$6.00	17%

The case for and against

Updated Sep 15, 2026

Bull case

Senti Biosciences is a clinical-stage biotechnology company with a positive outlook due to their gene circuit platform and promising pipeline. The company's current clinical trial for SENTI-202, a blood cancer treatment, has shown impressive results with the use of the "Donor X" phenotype, which is found in approximately 50% of adult donors and does not present any operational constraints. However, there are risks associated with financing and manufacturing that could impact future progress and share dilution for investors. Overall, the potential for success in the gene therapy space and the company's current progress make Senti Biosciences a promising investment opportunity.

Bear case

Senti Biosciences is a clinical stage biotechnology company focused on developing cell and gene therapies for incurable diseases through its proprietary gene circuit platform. However, while its lead candidate, SENTI-202, has shown promising results in a heavily pretreated AML population, there are still uncertainties around the regulatory approval and commercial potential of such therapies. Additionally, the company's need for additional financing and potential competition from other players in the cell therapy space pose risks to future profitability.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.